Who are Adecatumumab and FOLFOX's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TQB2440 injection + Trastuzumab + Docetaxel, RITUXIMAB + DHAP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adecatumumab-and-folfox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Adecatumumab and FOLFOX — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adecatumumab and FOLFOX (Adecatumumab and FOLFOX) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody, Chemotherapy. Area: Oncology.

phase 2 Monoclonal antibody, Chemotherapy EpCAM Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Adecatumumab and FOLFOX (Adecatumumab and FOLFOX) — Amgen Research (Munich) GmbH. Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adecatumumab and FOLFOX TARGET	Adecatumumab and FOLFOX	Amgen Research (Munich) GmbH	phase 2	Monoclonal antibody, Chemotherapy	EpCAM
TQB2440 injection + Trastuzumab + Docetaxel	TQB2440 injection + Trastuzumab + Docetaxel	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Targeted therapy, monoclonal antibody, chemotherapy	PD-1, HER2/neu
RITUXIMAB + DHAP	RITUXIMAB + DHAP	GlaxoSmithKline	phase 3	Monoclonal antibody, chemotherapy	CD20

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody, Chemotherapy class)

Amgen Research (Munich) GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adecatumumab and FOLFOX — Competitive Intelligence Brief. https://druglandscape.com/ci/adecatumumab-and-folfox. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab